Home › Employers › Pharbest Pharmaceuticals Inc.
Pharbest Pharmaceuticals Inc.: H-1B salaries and sponsorship
Pharbest Pharmaceuticals Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $66,500.
Does Pharbest Pharmaceuticals Inc. sponsor H-1B visas?
Pharbest Pharmaceuticals Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on May 15, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Chemist | 2 | $66,500 |
| Sr. Market Research Analyst | 1 | $90,000 |
| Regulatory Affairs Associate | 1 | $62,837 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $77,500 |
| FY2026 | 2 | $65,418 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Chemist | $68,000 Level I | Farmingdale, NY | May 15, 2026 | Sep 30, 2026 | Certified |
| Regulatory Affairs Associate | $62,837 Level I | Farmingdale, NY | Nov 7, 2025 | Nov 14, 2025 | Certified |
| Chemist | $65,000 Level I | Farmingdale, NY | Aug 29, 2023 | Oct 1, 2023 | Certified |
| Sr. Market Research Analyst | $90,000 Level II | Farmingdale, NY | Jul 7, 2023 | Sep 29, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).